Make Better Decisions - Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

Get the Book: Make Better Decisions

Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

PDF eBook: Just $10 Get Print Book on Amazon

Serving hundreds of leading biopharmaceutical companies globally:

Teva
Express Scripts
Baxter
QuintilesIMS
Federal Trade Commission
Deloitte

Generated: September 22, 2019

DrugPatentWatch Database Preview

Details for Patent: 6,395,294

  Try a free trial


See Plans and Pricing

« Back to Dashboard

Which drugs does patent 6,395,294 protect, and when does it expire?

Patent 6,395,294 protects TRIESENCE and is included in one NDA.

Summary for Patent: 6,395,294
Title: Method of visualization of the vitreous during vitrectomy
Abstract:A composition for rendering a vitreous cavity visible during a surgical procedure to alleviate a structural disorder caused by the vitreous in an eye, and a method of using the composition. The composition is a vitreous delineating agent that is translucent, opaque or semi-opaque and is in a formulation that may be a solution, a suspension or an emulsion. The agent may be a liposome or microsphere that may additionally contain a therapeutic agent. In use, the agent marks or delineates the vitreous cavity, allowing a surgeon to clearly visualize the entire cavity. Use of the method improves accuracy of a vitrectomy and thus prevents suboptimal outcomes or the need for repeated procedures.
Inventor(s): Peyman; Gholam A. (New Orleans, LA)
Assignee:
Application Number:09/482,779
Patent Claim Types:
see list of patent claims
Composition; Use; Dosage form; Formulation; Delivery;

Drugs Protected by US Patent 6,395,294

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate
Novartis Pharms Corp TRIESENCE triamcinolone acetonide INJECTABLE;INTRAVITREAL 022048-001 Nov 29, 2007 RX Yes Yes   Try a Free Trial   Try a Free Trial Y USE FOR DELINEATION (VISUALIZATION) DURING A VITRECTOMY SURGICAL PROCEDURE   Try a Free Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Patented / Exclusive Use >Submissiondate

Make Better Decisions: Try a trial or see plans & pricing

Serving hundreds of leading biopharmaceutical companies globally:

Cipla
Accenture
Johnson and Johnson
Colorcon
Merck
Medtronic

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.